HK17386A - Pharmaceutical formulation - Google Patents

Pharmaceutical formulation

Info

Publication number
HK17386A
HK17386A HK173/86A HK17386A HK17386A HK 17386 A HK17386 A HK 17386A HK 173/86 A HK173/86 A HK 173/86A HK 17386 A HK17386 A HK 17386A HK 17386 A HK17386 A HK 17386A
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
HK173/86A
Other languages
English (en)
Inventor
Barry William Burnstead
David John Rooke
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK17386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of HK17386A publication Critical patent/HK17386A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK173/86A 1980-09-27 1986-03-13 Pharmaceutical formulation HK17386A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031298 1980-09-27

Publications (1)

Publication Number Publication Date
HK17386A true HK17386A (en) 1986-03-21

Family

ID=10516342

Family Applications (1)

Application Number Title Priority Date Filing Date
HK173/86A HK17386A (en) 1980-09-27 1986-03-13 Pharmaceutical formulation

Country Status (15)

Country Link
US (1) US4537887A (el)
EP (1) EP0049061B1 (el)
JP (1) JPS5791921A (el)
AU (1) AU549321B2 (el)
CA (1) CA1187796A (el)
DE (1) DE3172028D1 (el)
ES (1) ES505803A0 (el)
GB (1) GB2084016B (el)
GR (1) GR75049B (el)
HK (1) HK17386A (el)
IE (1) IE51597B1 (el)
MY (1) MY8600353A (el)
NZ (1) NZ198241A (el)
PT (1) PT73686A (el)
ZA (1) ZA816272B (el)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59104319A (ja) * 1982-12-06 1984-06-16 Chugai Pharmaceut Co Ltd 抗菌剤およびそのキツト
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
ATE108996T1 (de) * 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
US5643902A (en) * 1990-04-26 1997-07-01 Pfizer Inc. Veterinary treatment
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
GB9413542D0 (en) * 1994-07-05 1994-08-24 Smithkline Beecham Plc Pharmaceutical formulations
CN1075022C (zh) * 1994-08-05 2001-11-21 康沃尔西药服务有限公司 湿度敏感性材料用的容器
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DZ1926A1 (fr) * 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
IL123563A (en) * 1995-09-07 2002-02-10 Smithkline Beecham Corp Pharmaceutical formulations comprising amoxycillin and clavulanate in a weight ratio between 14:1 and 16:1 inclusive
ITMI952354A1 (it) * 1995-11-16 1997-05-16 Smithkline Beecham Spa Composizione farmaceutica
US5801796A (en) * 1996-05-10 1998-09-01 International Business Machines Corporation Stacked parallax-free liquid crystal display cell
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
ES2201468T3 (es) * 1997-02-14 2004-03-16 Laboratoire Glaxosmithkline S.A.S. Preparacion farmaceutica que comprende amoxicilina y clavulanato.
US6296871B1 (en) * 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
US6177421B1 (en) 1999-05-04 2001-01-23 Fuisz International Ltd. Amoxicillin and clavulanate composition
IE990159A1 (en) * 1999-02-26 2000-09-20 Fuisz Internat Ltd Storage Stable Amoxycillin and Clavulanate Suspension Composition.
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
NZ517663A (en) * 1999-08-16 2006-02-24 Revaax Pharmaceuticals Llc Neurotherapeutic clavulanate composition and method
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
WO2002030392A2 (en) 2000-10-12 2002-04-18 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
EP1902708A1 (de) * 2006-09-25 2008-03-26 Losan Pharma GmbH Wirkstoff enthaltende stabilisierte feste Arzneimittelformen und Verfahren zu ihrer Herstellung
KR20100101574A (ko) 2007-10-26 2010-09-17 렉산 파마슈티컬스, 인코포레이티드 클라불란산의 제약 제제
EP2424498A1 (en) * 2009-04-29 2012-03-07 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
AU2014227598B2 (en) 2013-03-15 2018-12-06 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
GB1209634A (en) * 1967-06-29 1970-10-21 Rit Rech Ind Therapeut Stabilized antibiotic compositions for animal feeding and process for preparing them
DE2512247A1 (de) * 1975-03-20 1976-10-14 Thomae Gmbh Dr K Gegen feuchtigkeit stabilisierte presslinge mit feuchtigkeitsempfindlichen inhaltsstoffen
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en) * 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions

Also Published As

Publication number Publication date
GB2084016A (en) 1982-04-07
ES8307095A1 (es) 1983-06-16
JPS5791921A (en) 1982-06-08
EP0049061A1 (en) 1982-04-07
ES505803A0 (es) 1983-06-16
GR75049B (el) 1984-07-12
IE51597B1 (en) 1987-01-21
CA1187796A (en) 1985-05-28
DE3172028D1 (en) 1985-10-03
IE812232L (en) 1982-03-27
AU7568481A (en) 1982-04-08
NZ198241A (en) 1983-12-16
AU549321B2 (en) 1986-01-23
MY8600353A (en) 1986-12-31
GB2084016B (en) 1985-04-17
ZA816272B (en) 1982-09-29
PT73686A (pt) 1981-10-01
US4537887A (en) 1985-08-27
JPH0155244B2 (el) 1989-11-22
EP0049061B1 (en) 1985-08-28

Similar Documents

Publication Publication Date Title
DE3172028D1 (en) Pharmaceutical formulation
ZA828797B (en) Pharmaceutical formulation
ZA813465B (en) Pharmaceutical composition
PH19245A (en) Pharmaceutical preparations
DE3264782D1 (en) Medicinal formulation
HK53188A (en) Pharmaceutical formulations
ZA81136B (en) Pharmaceutical compositions
GB2072504B (en) Pharmaceutical compositions
ZA815700B (en) Pharmaceutical compositions
GB2074028B (en) Pharmaceutical formulations
MTP884B (en) Pharmaceutical preparationes
ZA81650B (en) Pharmaceutical preparations
DE3176849D1 (en) Pharmaceutical composition comprising 4-carbamoyl-imidazolium-5-olate
SG62587G (en) Pharmaceutical formulation
PT73952B (en) Pharmaceutical compositions
ZA815175B (en) Pharmaceutical composition
AU543418B2 (en) Pharmaceutical formulation
KE3581A (en) Pharmaceutical formulation
IE822854L (en) Pharmaceutical formulation
DK173981A (da) Fremgangsmaade til fremstilling af cis-9-(3-(3,5-dimethyl-1-piperazinyl) propyl) carbazol eller salte deraf og mallemprodukter for fremstillingen
ZA816940B (en) Pharmaceutical compositions
ZA812902B (en) Pharmaceutical compositions
PT73810B (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
PE Patent expired